FDA approves Utebzi as first oral carbapenem
Spero Therapeutics (NASDAQ:SPRO) and GSK (NYSE:GSK) announced on June 17, 2026, that the FDA has granted approval for Utebzi, an oral antibiotic designed for adults with complicated urinary tract infections (cUTIs).










